A Phase I/II Study of IVONESCIMAB in Recurrent Glioblastoma

No open prediction endpoints

Endpoints are classified and published by ProgramSignal analysts.

Key Facts

Primary Endpoints (CT.gov)

Eligibility Criteria

Inclusion Criteria: 1. Age ≥18 years 2. Karnofsky Performance Status (KPS) of 60 or greater 3. Recurrent supratentorial Glioblastoma that has progressed following standard therapy; patients must have previously been treated with radiation with or without temozolomide. 1. Patients will be eligible at first or second recurrence. 2. Patients must be greater than 12 weeks from completion of initial chemoradiation at the time of progression, with the exception that patients with biopsy-confirmed recurrent disease prior to this time window can be enrolled. 4. Diagnosis of Glioblastoma IDH-wildtype, WHO Grade 4 consistent with WHO CNS 2021 criteria. This will include patients with a diagnosis of molecular glioblastoma. 5. Measurable or evaluable disease per RANO criteria 6. A baseline MRI Brain no more than 14 days prior to study enrollment 7. Adequate Organ Function, with screening labs performed within 14 days of treatment initiation: a. Hematology (no blood transfusions or grow…

✦ Analyst Commentary

Expert commentary on why this trial matters and what to watch for.

Source